Valneva SE (VALN) Stock Forecast, Price Target & Predictions
VALN Stock Forecast
Valneva SE stock forecast is as follows: an average price target of $26.00 (represents a 470.18% upside from VALN’s last price of $4.56) and a rating consensus of 'Hold', based on 3 wall street analysts offering a 1-year stock forecast.
VALN Price Target
The average price target for Valneva SE (VALN) is $26.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $26.00 to $26.00. This represents a potential 470.18% upside from VALN's last price of $4.56.
VALN Analyst Ratings
According to 3 Wall Street analysts, Valneva SE's rating consensus is 'Hold'. The analyst rating breakdown for VALN stock is 0 'Strong Buy' (0.00%), 1 'Buy' (33.33%), 2 'Hold' (66.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Valneva SE Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 01, 2024 | Edward White | H.C. Wainwright | $26.00 | $7.39 | 251.83% | 470.18% |
The latest Valneva SE stock forecast, released on Jul 01, 2024 by Edward White from H.C. Wainwright, set a price target of $26.00, which represents a 251.83% increase from the stock price at the time of the forecast ($7.39), and a 470.18% increase from VALN last price ($4.56).
Valneva SE Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $26.00 |
| Last Closing Price | $4.56 | $4.56 | $4.56 |
| Upside/Downside | -100.00% | -100.00% | 470.18% |
In the current month, the average price target of Valneva SE stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Valneva SE's last price of $4.56. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 25, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 04, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 14, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jul 22, 2024 | Edward Jones | Underperform | Underperform | Hold |
| Jul 22, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 24, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 31, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Mar 22, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Mar 22, 2024 | Guggenheim | Underperform | Underperform | Hold |
| Sep 23, 2022 | Goldman Sachs | - | Neutral | Downgrade |
Valneva SE's last stock rating was published by H.C. Wainwright on Sep 25, 2024. The company gave VALN a "Buy" rating, the same as its previous rate.
Valneva SE Financial Forecast
Valneva SE Revenue Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | $33.51M | $111.40M | $156.68M | $71.38M | $21.85M | $278.24M | $22.35M | $24.29M |
| Avg Forecast | $60.22M | $49.06M | $44.73M | $71.99M | $76.82M | $45.07M | $34.46M | $33.11M | $158.27M | $115.89M | $20.49M | $22.92M | $174.40M | $156.12M | $29.33M |
| High Forecast | $60.31M | $51.89M | $46.26M | $74.50M | $81.25M | $46.24M | $36.45M | $35.02M | $167.41M | $115.89M | $20.49M | $22.92M | $174.40M | $156.12M | $29.33M |
| Low Forecast | $60.12M | $47.82M | $43.21M | $69.49M | $74.88M | $43.91M | $33.59M | $32.27M | $154.27M | $115.89M | $20.49M | $22.92M | $174.40M | $156.12M | $29.33M |
| # Analysts | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | 1.01% | 0.70% | 1.35% | 3.48% | 0.95% | 1.60% | 0.14% | 0.83% |
Valneva SE's average Quarter revenue forecast for Jun 23 based on 1 analysts is $34.46M, with a low forecast of $33.59M, and a high forecast of $36.45M. VALN's average Quarter revenue forecast represents a 2.84% increase compared to the company's last Quarter revenue of $33.51M (Mar 23).
Valneva SE EBITDA Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | $-16.32M | $-56.15M | $93.30M | $-142.61M | $-18.41M | $176.34M | $-160.21M | $-53.84M |
| Avg Forecast | $-13.58M | $-11.06M | $-10.08M | $-16.23M | $-17.32M | $-10.16M | $-7.77M | $-7.46M | $-35.68M | $-31.09M | $-5.50M | $-6.15M | $-46.78M | $-41.88M | $-132.86M |
| High Forecast | $-13.55M | $-10.78M | $-9.74M | $-15.67M | $-16.88M | $-9.90M | $-7.57M | $-7.28M | $-34.78M | $-31.09M | $-5.50M | $-6.15M | $-46.78M | $-41.88M | $-106.28M |
| Low Forecast | $-13.60M | $-11.70M | $-10.43M | $-16.79M | $-18.32M | $-10.42M | $-8.22M | $-7.89M | $-37.74M | $-31.09M | $-5.50M | $-6.15M | $-46.78M | $-41.88M | $-159.43M |
| Surprise % | - | - | - | - | - | - | - | 2.19% | 1.57% | -3.00% | 25.95% | 2.99% | -3.77% | 3.83% | 0.41% |
1 analysts predict VALN's average Quarter EBITDA for Dec 22 to be $-35.68M, with a high of $-34.78M and a low of $-37.74M. This is -138.24% lower than Valneva SE's previous annual EBITDA (Sep 22) of $93.30M.
Valneva SE Net Income Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | $-18.13M | $-44.20M | $72.42M | $-145.45M | $-26.04M | $172.51M | $-159.53M | $-58.70M |
| Avg Forecast | $-23.53M | $-31.32M | $-41.80M | $137.13M | $11.23M | $-55.94M | $-33.24M | $-46.89M | $29.51M | $87.36M | $-144.34M | $-49.48M | $258.02M | $185.75M | $-144.85M |
| High Forecast | $-16.81M | $-30.30M | $-40.43M | $147.42M | $51.65M | $-54.11M | $-32.15M | $-45.35M | $31.73M | $87.36M | $-144.34M | $-49.48M | $258.02M | $185.75M | $-115.88M |
| Low Forecast | $-30.25M | $-33.68M | $-44.94M | $132.63M | $-29.19M | $-60.14M | $-35.73M | $-50.41M | $28.55M | $87.36M | $-144.34M | $-49.48M | $258.02M | $185.75M | $-173.82M |
| Surprise % | - | - | - | - | - | - | - | 0.39% | -1.50% | 0.83% | 1.01% | 0.53% | 0.67% | -0.86% | 0.41% |
Valneva SE's average Quarter net income forecast for Dec 22 is $29.51M, with a range of $28.55M to $31.73M. VALN's average Quarter net income forecast represents a -59.24% decrease compared to the company's last Quarter net income of $72.42M (Sep 22).
Valneva SE SG&A Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | $19.02M | $21.23M | $12.49M | $16.06M | $7.80M | $24.59M | $16.12M | $15.60M |
| Avg Forecast | $20.94M | $17.06M | $15.56M | $25.03M | $26.71M | $15.67M | $11.98M | $11.51M | $55.03M | $40.10M | $7.09M | $7.93M | $60.35M | $54.02M | $10.15M |
| High Forecast | $20.97M | $18.04M | $16.09M | $25.90M | $28.25M | $16.08M | $12.68M | $12.18M | $58.21M | $40.10M | $7.09M | $7.93M | $60.35M | $54.02M | $10.15M |
| Low Forecast | $20.91M | $16.63M | $15.03M | $24.16M | $26.04M | $15.27M | $11.68M | $11.22M | $53.65M | $40.10M | $7.09M | $7.93M | $60.35M | $54.02M | $10.15M |
| Surprise % | - | - | - | - | - | - | - | 1.65% | 0.39% | 0.31% | 2.27% | 0.98% | 0.41% | 0.30% | 1.54% |
Valneva SE's average Quarter SG&A projection for Jun 23 is $11.98M, based on 1 Wall Street analysts, with a range of $11.68M to $12.68M. The forecast indicates a -37.01% fall compared to VALN last annual SG&A of $19.02M (Mar 23).
Valneva SE EPS Forecast
| Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | $-0.26 | $-0.77 | $1.57 | $-3.15 | $-0.48 | $3.18 | $-2.94 | $-1.27 |
| Avg Forecast | $-0.18 | $-0.24 | $-0.32 | $1.04 | $0.09 | $-0.43 | $-0.25 | $-0.36 | $0.22 | $0.63 | $-1.04 | $-0.36 | $1.86 | $1.34 | $-0.87 |
| High Forecast | $-0.13 | $-0.23 | $-0.31 | $1.12 | $0.39 | $-0.41 | $-0.24 | $-0.34 | $0.24 | $0.63 | $-1.04 | $-0.36 | $1.86 | $1.34 | $-0.87 |
| Low Forecast | $-0.23 | $-0.26 | $-0.34 | $1.01 | $-0.22 | $-0.46 | $-0.27 | $-0.38 | $0.22 | $0.63 | $-1.04 | $-0.36 | $1.86 | $1.34 | $-0.87 |
| Surprise % | - | - | - | - | - | - | - | 0.73% | -3.43% | 2.49% | 3.03% | 1.35% | 1.71% | -2.20% | 1.45% |
According to 1 Wall Street analysts, Valneva SE's projected average Quarter EPS for Dec 22 is $0.22, with a low estimate of $0.22 and a high estimate of $0.24. This represents a -85.71% decrease compared to VALN previous annual EPS of $1.57 (Sep 22).
Valneva SE Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SAGE | Sage Therapeutics | $4.91 | $38.89 | 692.06% | Hold |
| VALN | Valneva SE | $4.56 | $26.00 | 470.18% | Hold |
| SLS | SELLAS Life Sciences Group | $1.29 | $7.00 | 442.64% | Buy |
| OPT | Opthea | $3.26 | $14.00 | 329.45% | Buy |
| ANEB | Anebulo Pharmaceuticals | $1.52 | $6.00 | 294.74% | Buy |
| CCCC | C4 Therapeutics | $4.15 | $13.50 | 225.30% | Buy |
| TIL | Instil Bio | $26.20 | $78.25 | 198.66% | Hold |
| STOK | Stoke Therapeutics | $11.61 | $30.60 | 163.57% | Buy |
| NUVB | Nuvation Bio | $2.59 | $6.75 | 160.62% | Buy |
| ELYM | Eliem Therapeutics | $5.11 | $13.00 | 154.40% | Buy |
| CGEM | Cullinan Oncology | $13.10 | $31.50 | 140.46% | Buy |
| MLYS | Mineralys Therapeutics | $12.86 | $30.00 | 133.28% | Buy |
| TYRA | Tyra Biosciences | $16.21 | $31.75 | 95.87% | Buy |
| CNTB | Connect Biopharma | $0.98 | $1.50 | 53.06% | Buy |
| EWTX | Edgewise Therapeutics | $31.51 | $45.00 | 42.81% | Buy |
| THRD | Third Harmonic Bio | $12.46 | $16.15 | 29.61% | Buy |
| GRPH | LENZ Therapeutics | $3.18 | $4.00 | 25.79% | Hold |
| RVMD | Revolution Medicines, Inc. Warrant | $56.47 | $60.63 | 7.37% | Buy |